254 related articles for article (PubMed ID: 23610119)
1. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer.
Li J; Humphreys K; Eriksson L; Edgren G; Czene K; Hall P
J Clin Oncol; 2013 Jun; 31(18):2249-56. PubMed ID: 23610119
[TBL] [Abstract][Full Text] [Related]
2. Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.
van Nes JG; Beex LV; Seynaeve C; Putter H; Sramek A; Lardenoije S; Duijm-de Carpentier M; Van Rongen I; Nortier JW; Zonderland HM; van de Velde CJ
Acta Oncol; 2015 Mar; 54(3):349-60. PubMed ID: 25383451
[TBL] [Abstract][Full Text] [Related]
3. Mammographic Density Reduction as a Prognostic Marker for Postmenopausal Breast Cancer: Results Using a Joint Longitudinal-Survival Modeling Approach.
Andersson TM; Crowther MJ; Czene K; Hall P; Humphreys K
Am J Epidemiol; 2017 Nov; 186(9):1065-1073. PubMed ID: 28633324
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
[TBL] [Abstract][Full Text] [Related]
5. Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.
Brentnall AR; Warren R; Harkness EF; Astley SM; Wiseman J; Fox J; Fox L; Eriksson M; Hall P; Cuzick J; Evans DG; Howell A
Breast Cancer Res; 2020 Sep; 22(1):101. PubMed ID: 32993747
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.
Cuzick J; Warwick J; Pinney E; Duffy SW; Cawthorn S; Howell A; Forbes JF; Warren RM
J Natl Cancer Inst; 2011 May; 103(9):744-52. PubMed ID: 21483019
[TBL] [Abstract][Full Text] [Related]
7. Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.
Thorén L; Eriksson M; Lindh JD; Czene K; Bergh J; Eliasson E; Hall P; Margolin S
Breast Cancer Res Treat; 2021 Dec; 190(3):451-462. PubMed ID: 34570302
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen in women with breast cancer and mammographic density.
Meggiorini ML; Labi L; Vestri AR; Porfiri LM; Savelli S; De Felice C
Eur J Gynaecol Oncol; 2008; 29(6):598-601. PubMed ID: 19115686
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Change in Mammographic Density among ER-Positive Breast Cancer Patients Using Tamoxifen.
Nyante SJ; Sherman ME; Pfeiffer RM; Berrington de Gonzalez A; Brinton LA; Bowles EJ; Hoover RN; Glass A; Gierach GL
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):212-6. PubMed ID: 26545407
[TBL] [Abstract][Full Text] [Related]
11. Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change.
Gabrielson M; Hammarström M; Bergqvist J; Lång K; Rosendahl AH; Borgquist S; Hellgren R; Czene K; Hall P
Int J Cancer; 2024 Jul; 155(2):339-351. PubMed ID: 38554131
[TBL] [Abstract][Full Text] [Related]
12. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
[TBL] [Abstract][Full Text] [Related]
13. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
Filipits M; Rudas M; Heinzl H; Jakesz R; Kubista E; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Nader A; Stierer M; Gnant MF;
Clin Cancer Res; 2009 Sep; 15(18):5888-94. PubMed ID: 19723645
[TBL] [Abstract][Full Text] [Related]
14. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
15. Mammographic density as a predictor of breast cancer survival: the Multiethnic Cohort.
Maskarinec G; Pagano IS; Little MA; Conroy SM; Park SY; Kolonel LN
Breast Cancer Res; 2013 Jan; 15(1):R7. PubMed ID: 23339436
[TBL] [Abstract][Full Text] [Related]
16. Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I.
Warwick J; Birke H; Stone J; Warren RM; Pinney E; Brentnall AR; Duffy SW; Howell A; Cuzick J
Breast Cancer Res; 2014 Oct; 16(5):451. PubMed ID: 25292294
[TBL] [Abstract][Full Text] [Related]
17. Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer.
Kim WH; Cho N; Kim YS; Yi A
Eur Radiol; 2018 Aug; 28(8):3176-3184. PubMed ID: 29626240
[TBL] [Abstract][Full Text] [Related]
18. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.
Nyante SJ; Sherman ME; Pfeiffer RM; Berrington de Gonzalez A; Brinton LA; Aiello Bowles EJ; Hoover RN; Glass A; Gierach GL
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663687
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]